Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Mitomycin C in HER2-Expressing NMIBC
NCT07646145Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in non-muscle-invasive bladder cancer (NMIBC), sponsored by Shanxi Cancer Hospital. Started Apr 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07646145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646145.